Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy
Brief Summary: The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin.


Options:
A: Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Glimepiride
B: Arm Label: metformin + glimepiride + pioglitazone + albiglutide placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo to match albiglutide, Drug: metformin, Drug: glimepiride, Drug: pioglitazone | Arm Label: metformin + glimepiride + pioglitazone placebo + albiglutide; Type: EXPERIMENTAL; Interventions: Biological: albiglutide, Drug: metformin, Drug: glimepiride, Drug: placebo to match pioglitazone | Arm Label: met + glimepiride + pioglitazone placebo + albiglutide placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo to match albiglutide, Drug: metformin, Drug: glimepiride, Drug: placebo to match pioglitazone | Intervention Type: DRUG; Name: placebo to match albiglutide; Assigned to Arm(s): met + glimepiride + pioglitazone placebo + albiglutide placebo, metformin + glimepiride + pioglitazone + albiglutide placebo | Intervention Type: BIOLOGICAL; Name: albiglutide; Assigned to Arm(s): metformin + glimepiride + pioglitazone placebo + albiglutide | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): met + glimepiride + pioglitazone placebo + albiglutide placebo, metformin + glimepiride + pioglitazone + albiglutide placebo, metformin + glimepiride + pioglitazone placebo + albiglutide | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): met + glimepiride + pioglitazone placebo + albiglutide placebo, metformin + glimepiride + pioglitazone + albiglutide placebo, metformin + glimepiride + pioglitazone placebo + albiglutide | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): metformin + glimepiride + pioglitazone + albiglutide placebo | Intervention Type: DRUG; Name: placebo to match pioglitazone; Assigned to Arm(s): met + glimepiride + pioglitazone placebo + albiglutide placebo, metformin + glimepiride + pioglitazone placebo + albiglutide
C: Arm Label: Vildagliptin & metformin; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin | Arm Label: Glibenclamide & metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glibenclamide, Drug: Metformin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin & metformin | Intervention Type: DRUG; Name: Glibenclamide; Assigned to Arm(s): Glibenclamide & metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glibenclamide & metformin, Vildagliptin & metformin
D: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A

Answer: A